

**REPORT ON REVIEW OF INTERIM FINANCIAL INFORMATION
BY THE INDEPENDENT CERTIFIED PUBLIC ACCOUNTANTS**

**TO THE BOARD OF DIRECTORS
HEALTHLEAD PUBLIC COMPANY LIMITED**

We have reviewed the consolidated statement of financial position of Healthlead Public Company Limited and its subsidiaries and the separate statement of financial position of Healthlead Public Company Limited as June 30, 2026, and the related consolidated and separate statements of comprehensive income for the three-month and six-month periods ended June 30, 2026, and the related consolidated and separate statements of changes in shareholders' equity and cash flows for the six-month period ended June 30, 2026, and the condensed notes to the financial statements. The Company's management is responsible for the preparation and presentation of this interim financial information in accordance with Thai Accounting Standard No. 34 "Interim Financial Reporting". Our responsibility is to express a conclusion on this interim financial information based on our review.

Scope of Review

We conducted our review in accordance with Thai Standard on Review Engagements 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity". A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Thai Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Conclusion

Based on our review, nothing has come to our attention that causes us to believe that the aforementioned interim financial information is not prepared, in all material respects, in accordance with Thai Accounting Standard No. 34 "Interim Financial Reporting".

**BANGKOK
August 13, 2026**

**Lasita Magut
Certified Public Accountant (Thailand)
Registration No. 9039
DELOITTE TOUCHE TOHMATSU JAIYOS AUDIT CO., LTD.**

HEALTHLEAD PUBLIC COMPANY LIMITED AND ITS SUBSIDIARIES
STATEMENTS OF FINANCIAL POSITION
AS AT JUNE 30, 2026

UNIT : BAHT

	Notes	CONSOLIDATED FINANCIAL STATEMENTS		SEPARATE FINANCIAL STATEMENTS	
		As at June 30, 2026	As at December 31, 2025	As at June 30, 2026	As at December 31, 2025
		“UNAUDITED”		“UNAUDITED”	
ASSETS					
CURRENT ASSETS					
Cash and cash equivalents	6	38,856,034	37,427,894	138,859	1,521,666
Trade and other current receivables	7	44,407,320	54,061,301	5,127,940	6,184,709
Inventories	8	358,397,583	308,707,075	-	-
Other current financial assets	9	372,251,402	511,902,866	324,276,835	422,103,650
Other current assets		795,981	771,677	32,186	14,386
Total Current Assets		<u>814,708,320</u>	<u>912,870,813</u>	<u>329,575,820</u>	<u>429,824,411</u>
NON-CURRENT ASSETS					
Restricted bank deposits		240,000	240,000	-	-
Other non-current financial assets	9	7,051,291	7,095,925	7,051,291	7,095,925
Investments in subsidiaries	10	-	-	529,071,474	520,686,197
Property, plant and equipment		233,060,524	248,784,081	3,179,360	3,319,794
Right-of-use assets		273,301,846	302,676,570	8,555,865	9,489,211
Goodwill		15,617,283	15,617,283	-	-
Other intangible assets other than goodwill		8,840,156	9,480,878	248,910	113,661
Deferred tax assets		8,020,640	5,891,627	177,768	-
Other non-current assets	11	33,879,150	33,251,088	726,500	743,300
Total Non-current Assets		<u>580,010,890</u>	<u>623,037,452</u>	<u>549,011,168</u>	<u>541,448,088</u>
TOTAL ASSETS		<u><u>1,394,719,210</u></u>	<u><u>1,535,908,265</u></u>	<u><u>878,586,988</u></u>	<u><u>971,272,499</u></u>

See condensed notes to the financial statements

HEALTHLEAD PUBLIC COMPANY LIMITED AND ITS SUBSIDIARIES
STATEMENTS OF FINANCIAL POSITION (CONTINUED)
AS AT JUNE 30, 2026

UNIT : BAHT

	Notes	CONSOLIDATED FINANCIAL STATEMENTS		SEPARATE FINANCIAL STATEMENTS	
		As at June 30, 2026 “UNAUDITED”	As at December 31, 2025	As at June 30, 2026 “UNAUDITED”	As at December 31, 2025
LIABILITIES AND SHAREHOLDERS' EQUITY					
CURRENT LIABILITIES					
Trade and other current payables	12	191,722,859	213,317,543	4,278,329	7,105,887
Current portion of lease liabilities		46,796,591	44,670,347	1,505,094	1,605,645
Corporate income tax payable		4,164,843	9,091,399	2,279,904	1,836,276
Other current liabilities		1,243,905	1,613,181	268,180	301,209
Total Current Liabilities		243,928,198	268,692,470	8,331,507	10,849,017
NON-CURRENT LIABILITIES					
Lease liabilities		245,090,802	273,742,820	8,542,812	9,233,738
Deferred tax liabilities		-	603,794	-	457,635
Provision for dismantling and removal cost		13,176,357	12,268,960	343,500	343,500
Non-current provisions for employee benefits		8,497,215	7,436,642	5,266,548	4,854,588
Other non-current liabilities		5,852,084	5,562,074	78,846	83,295
Total Non-current Liabilities		272,616,458	299,614,290	14,231,706	14,972,756
TOTAL LIABILITIES		516,544,656	568,306,760	22,563,213	25,821,773
SHAREHOLDERS' EQUITY					
SHARE CAPITAL					
Authorized share capital					
272,000,000 ordinary shares of Baht 0.50 each		136,000,000	136,000,000	136,000,000	136,000,000
Issued and paid-up share capital					
272,000,000 ordinary shares of Baht 0.50 each, fully paid		136,000,000	136,000,000	136,000,000	136,000,000
Share premium on ordinary shares		647,639,270	647,639,270	647,639,270	647,639,270
Surplus on a business combination under common control		22,151,112	22,151,112	-	-
RETAINED EARNINGS					
Appropriated					
Legal reserve	13	13,600,000	13,600,000	13,600,000	13,600,000
Treasury shares reserve		121,207,692	69,575,916	121,207,692	69,575,916
Unappropriated		58,784,172	148,211,123	58,784,505	148,211,456
Treasury shares		(121,207,692)	(69,575,916)	(121,207,692)	(69,575,916)
TOTAL SHAREHOLDERS' EQUITY		878,174,554	967,601,505	856,023,775	945,450,726
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY		1,394,719,210	1,535,908,265	878,586,988	971,272,499

See condensed notes to the financial statements

HEALTHLEAD PUBLIC COMPANY LIMITED AND ITS SUBSIDIARIES
STATEMENTS OF COMPREHENSIVE INCOME
FOR THE THREE-MONTH PERIOD ENDED JUNE 30, 2026
“UNAUDITED”

UNIT : BAHT

	Note	CONSOLIDATED FINANCIAL STATEMENTS		SEPARATE FINANCIAL STATEMENTS	
		2026	2025	2026	2025
REVENUES					
Revenue from sales		526,753,582	548,297,105	-	-
Revenue from management fee		-	-	14,720,995	15,260,792
Other income		9,271,502	9,031,519	69,434	40,600
Total Revenues		536,025,084	557,328,624	14,790,429	15,301,392
EXPENSES					
Costs of sales		(400,152,419)	(414,787,219)	-	-
Distribution costs		(104,200,012)	(98,570,039)	-	-
Administrative expenses		(28,454,058)	(21,974,118)	(10,849,927)	(10,432,473)
Other gains		935,569	2,129,175	746,906	1,854,698
Total Expenses		(531,870,920)	(533,202,201)	(10,103,021)	(8,577,775)
Profit from operating activities		4,154,164	24,126,423	4,687,408	6,723,617
Finance income		530,122	1,326,124	505,737	1,239,046
Finance costs		(4,433,330)	(4,092,598)	(141,465)	(103,757)
Reversal of impairment loss (impairment loss)					
determined in accordance with TFRS 9		(40,711)	14,771	(55,624)	(25,730)
Share of profit (loss) of subsidiaries accounted for using					
the equity method		-	-	(3,686,108)	10,556,727
Profit before income tax		210,245	21,374,720	1,309,948	18,389,903
Tax income (expense)		101,225	(4,570,704)	(998,478)	(1,585,887)
PROFIT FOR THE PERIODS		311,470	16,804,016	311,470	16,804,016
Total comprehensive income for the periods		311,470	16,804,016	311,470	16,804,016
Profit attributable to					
Owners of the parent		311,470	16,804,016	311,470	16,804,016
Profit for the periods		311,470	16,804,016	311,470	16,804,016
Total comprehensive income attributable to					
Owners of the parent		311,470	16,804,016	311,470	16,804,016
Total comprehensive income for the periods		311,470	16,804,016	311,470	16,804,016
Earnings per share					
Basic earnings per share	15	0.001	0.06	0.001	0.06

See condensed notes to the financial statements

HEALTHLEAD PUBLIC COMPANY LIMITED AND ITS SUBSIDIARIES
STATEMENTS OF COMPREHENSIVE INCOME
FOR THE SIX-MONTH PERIOD ENDED JUNE 30, 2026
“UNAUDITED”

UNIT : BAHT

	Notes	CONSOLIDATED FINANCIAL STATEMENTS		SEPARATE FINANCIAL STATEMENTS	
		2026	2025	2026	2025
REVENUES					
Revenue from sales		1,111,886,272	1,118,097,394	-	-
Revenue from management fee		-	-	31,042,472	31,338,718
Other income		18,770,795	17,806,188	120,583	81,100
Total Revenues		<u>1,130,657,067</u>	<u>1,135,903,582</u>	<u>31,163,055</u>	<u>31,419,818</u>
EXPENSES					
Costs of sales		(846,305,153)	(852,640,967)	-	-
Distribution costs		(206,061,458)	(191,697,285)	-	-
Administrative expenses		(50,339,557)	(43,710,132)	(20,985,918)	(20,097,126)
Other gains		2,894,078	4,224,820	2,115,386	3,649,852
Total Expenses		<u>(1,099,812,090)</u>	<u>(1,083,823,564)</u>	<u>(18,870,532)</u>	<u>(16,447,274)</u>
Profit from operating activities		<u>30,844,977</u>	<u>52,080,018</u>	<u>12,292,523</u>	<u>14,972,544</u>
Finance income		1,117,013	2,969,959	1,092,628	2,914,524
Finance costs		(8,914,400)	(8,065,147)	(288,600)	(211,260)
Reversal of impairment loss (impairment loss)					
determined in accordance with TFRS 9		36,565	125,421	(20,892)	115,387
Share of profit of subsidiaries accounted for using					
the equity method	10	-	-	8,385,277	23,046,715
Profit before income tax		<u>23,084,155</u>	<u>47,110,251</u>	<u>21,460,936</u>	<u>40,837,910</u>
Income tax expenses		<u>(4,231,222)</u>	<u>(9,847,365)</u>	<u>(2,608,003)</u>	<u>(3,575,024)</u>
PROFIT FOR THE PERIODS		<u>18,852,933</u>	<u>37,262,886</u>	<u>18,852,933</u>	<u>37,262,886</u>
Total comprehensive income for the periods		<u><u>18,852,933</u></u>	<u><u>37,262,886</u></u>	<u><u>18,852,933</u></u>	<u><u>37,262,886</u></u>
Profit attributable to:					
Owners of the parent		<u>18,852,933</u>	<u>37,262,886</u>	<u>18,852,933</u>	<u>37,262,886</u>
Profit for the periods		<u><u>18,852,933</u></u>	<u><u>37,262,886</u></u>	<u><u>18,852,933</u></u>	<u><u>37,262,886</u></u>
Total comprehensive income attributable to:					
Owners of the parent		<u>18,852,933</u>	<u>37,262,886</u>	<u>18,852,933</u>	<u>37,262,886</u>
Total comprehensive income for the periods		<u><u>18,852,933</u></u>	<u><u>37,262,886</u></u>	<u><u>18,852,933</u></u>	<u><u>37,262,886</u></u>
Earnings per share					
Basic earnings per share	15	<u>0.07</u>	<u>0.14</u>	<u>0.07</u>	<u>0.14</u>

See condensed notes to the financial statements

HEALTHLEAD PUBLIC COMPANY LIMITED AND ITS SUBSIDIARIES
STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY
FOR THE SIX-MONTH PERIOD ENDED JUNE 30, 2026
“UNAUDITED”

UNIT : BAHT

Notes	CONSOLIDATED FINANCIAL STATEMENTS								
	Issued and paid-up share capital	Share premium on ordinary shares	Surplus on business combination under common control	Retained earnings			Treasury shares	Total shareholders' equity	
				Appropriated		Unappropriated			
				Treasury share					
				Legal reserve	reserve				
Balance as at January 1, 2025	136,000,000	647,639,270	22,151,112	13,600,000	-	186,433,543	-	1,005,823,925	
Change in shareholder's equity									
Dividend paid	19	-	-	-	-	(46,239,983)	-	(46,239,983)	
Total comprehensive income for the period		-	-	-	-	37,262,886	-	37,262,886	
Treasury shares	14	-	-	-	28,062,949	(28,062,949)	(28,062,949)	(28,062,949)	
Balance as at June 30, 2025		136,000,000	647,639,270	22,151,112	13,600,000	28,062,949	149,393,497	(28,062,949)	968,783,879
Balance as at January 1, 2026		136,000,000	647,639,270	22,151,112	13,600,000	69,575,916	148,211,123	(69,575,916)	967,601,505
Change in shareholder's equity									
Dividend paid	19	-	-	-	-	-	(56,648,108)	-	(56,648,108)
Total comprehensive income for the period		-	-	-	-	-	18,852,933	-	18,852,933
Treasury shares	14	-	-	-	-	51,631,776	(51,631,776)	(51,631,776)	(51,631,776)
Balance as at June 30, 2026		136,000,000	647,639,270	22,151,112	13,600,000	121,207,692	58,784,172	(121,207,692)	878,174,554

See condensed notes to the financial statements

HEALTHLEAD PUBLIC COMPANY LIMITED AND ITS SUBSIDIARIES
STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (CONTINUED)
FOR THE SIX-MONTH PERIOD ENDED JUNE 30, 2026
“UNAUDITED”

UNIT : BAHT

Notes		SEPARATE FINANCIAL STATEMENTS						
		Issued and paid-up share capital	Share premium on ordinary shares	Retained earnings			Total shareholders' equity	
				Appropriated		Unappropriated		
				Legal reserve	Treasury share reserve			Treasury shares
Balance as at January 1, 2025		136,000,000	647,639,270	13,600,000	-	186,433,876	-	983,673,146
Change in shareholder's equity								
Dividend paid	19	-	-	-	-	(46,239,983)	-	(46,239,983)
Total comprehensive income for the period		-	-	-	-	37,262,886	-	37,262,886
Treasury shares	14	-	-	-	28,062,949	(28,062,949)	(28,062,949)	(28,062,949)
Balance as at June 30, 2025		136,000,000	647,639,270	13,600,000	28,062,949	149,393,830	(28,062,949)	946,633,100
Balance as at January 1, 2026		136,000,000	647,639,270	13,600,000	69,575,916	148,211,456	(69,575,916)	945,450,726
Change in shareholder's equity								
Dividend paid	19	-	-	-	-	(56,648,108)	-	(56,648,108)
Total comprehensive income for the period		-	-	-	-	18,852,933	-	18,852,933
Treasury shares	14	-	-	-	51,631,776	(51,631,776)	(51,631,776)	(51,631,776)
Balance as at June 30, 2026		136,000,000	647,639,270	13,600,000	121,207,692	58,784,505	(121,207,692)	856,023,775

See condensed notes to the financial statements

HEALTHLEAD PUBLIC COMPANY LIMITED AND ITS SUBSIDIARIES
STATEMENTS OF CASH FLOWS
FOR THE SIX-MONTH PERIOD ENDED JUNE 30, 2026
“UNAUDITED”

UNIT : BAHT

	Notes	CONSOLIDATED FINANCIAL STATEMENTS		SEPARATE FINANCIAL STATEMENTS	
		2026	2025	2026	2025
CASH FLOWS FROM OPERATING ACTIVITIES					
Profit for the periods		18,852,933	37,262,886	18,852,933	37,262,886
Adjustments for					
Income tax expenses		4,231,222	9,847,365	2,608,003	3,575,024
Depreciation and amortization		49,787,114	44,644,974	1,449,286	1,378,851
Gain on write-off and modification of lease liabilities, net of right-of-use assets		(1,049,652)	-	-	-
Impairment loss recognized in profit or loss (reversal)		(36,565)	(125,421)	20,892	(115,387)
Loss on values in inventories adjustment and write-off (reversal)		157,256	118,416	-	-
Provision for dismantling and removal cost		-	10,019	-	-
Provisions for employee benefits		1,060,573	871,210	411,960	442,286
Gain on fair value adjustment of other financial assets		(2,894,078)	(4,224,820)	(2,115,386)	(3,649,852)
Loss on impairment of property, plant and equipment		4,674,437	-	-	-
Loss (Gain) on disposal of equipment		1,823,572	(224,760)	(594)	-
Share of profit from subsidiaries		-	-	(8,385,277)	(23,046,715)
Finance income		(1,117,013)	(2,969,959)	(1,092,628)	(2,914,524)
Finance costs		8,914,400	8,065,147	288,600	211,260
		84,404,199	93,275,057	12,037,789	13,143,829
Changes in operating assets and liabilities					
Operating assets (increase) decrease					
Trade and other current receivables		8,055,693	3,162,159	339,350	(131,339)
Inventories		(49,847,764)	(21,175,970)	-	-
Other current assets		(24,304)	(137,334)	(17,800)	(3,758)
Other non-current assets		(1,254,084)	(697,618)	16,800	20,000
Operating liabilities increase (decrease)					
Trade and other current payables		(19,299,700)	21,263,107	(970,625)	(603,721)
Other current liabilities		(369,276)	(175,368)	(33,029)	11,465
Provision for dismantling and removal cost		-	(63,414)	-	-
Other non-current liabilities		290,010	703,519	(4,449)	4,094
Net cash flows provided by operation		21,954,774	96,154,138	11,368,036	12,440,570
Income tax paid		(11,890,585)	(12,568,258)	(2,799,778)	(3,464,040)
Net cash flows provided by operating activities		10,064,189	83,585,880	8,568,258	8,976,530

HEALTHLEAD PUBLIC COMPANY LIMITED AND ITS SUBSIDIARIES
STATEMENTS OF CASH FLOWS (CONTINUED)
FOR THE SIX-MONTH PERIOD ENDED JUNE 30, 2026
“UNAUDITED”

UNIT : BAHT

	Notes	CONSOLIDATED FINANCIAL STATEMENTS		SEPARATE FINANCIAL STATEMENTS	
		2026	2025	2026	2025
CASH FLOWS FROM INVESTING ACTIVITIES					
Cash received from sell of unit trust		716,446,312	172,444,073	169,595,275	37,258,594
Cash paid for purchase of unit trust		(623,560,693)	(275,330,563)	(119,312,998)	(144,283,100)
Cash received from maturity of bonds		50,000,000	45,000,000	50,000,000	45,000,000
Cash paid for purchase of bonds		-	(45,100,321)	-	(45,100,321)
Cash received from disposal of equipment		6,328	261,364	888	-
Cash paid for purchase of plant and equipment	5.1	(12,280,765)	(20,140,358)	(400,183)	(214,993)
Cash paid for purchase of intangible assets		(372,490)	(77,690)	(168,850)	(32,540)
Cash received from loans to a related company		-	-	-	35,000,000
Interest received		1,518,427	3,321,974	1,493,713	3,268,644
Net cash flows provide by (used in) investing activities		131,757,119	(119,621,521)	101,207,845	(69,103,716)
CASH FLOWS FROM FINANCING ACTIVITIES					
Cash paid for lease liabilities	5.2	(30,314,258)	(25,646,521)	(1,080,000)	(846,000)
Cash paid for treasury shares		(53,430,802)	(27,199,417)	(53,430,802)	(27,199,417)
Dividend paid	19	(56,648,108)	(46,239,983)	(56,648,108)	(46,239,983)
Interest paid	5.2	-	(3,613)	-	-
Net cash flows used in financing activities		(140,393,168)	(99,089,534)	(111,158,910)	(74,285,400)
Net increase (decrease) in cash and cash equivalents		1,428,140	(135,125,175)	(1,382,807)	(134,412,586)
Cash and cash equivalents as at January 1,		37,427,894	168,667,011	1,521,666	137,374,964
Cash and cash equivalents as at June 30,		38,856,034	33,541,836	138,859	2,962,378

See condensed notes to the financial statements

HEALTHLEAD PUBLIC COMPANY LIMITED AND ITS SUBSIDIARIES
CONDENSED NOTES TO THE FINANCIAL STATEMENTS
FOR THE THREE-MONTH AND SIX-MONTH PERIODS ENDED JUNE 30, 2026
“UNAUDITED”

1. THE COMPANY’S OPERATION AND GENERAL INFORMATION

Healthlead Public Company Limited (“the Company”), is incorporated in Thailand and has its registered office at 99/4, Moo 10, Bang Muang Subdistrict, Bang Yai District, Nonthaburi.

On December 9, 2020, the Company registered the conversion from a private company into a public limited company and listed its share in the Market for Alternative Investment (MAI) on December 3, 2021.

As at June 30, 2026 and December 31, 2025, the Company’s major and ultimate shareholder is Bhandhukanonda family which is holding 41.64% and 39.12% of the Company’s shares, respectively.

The principal businesses of the Company and its subsidiaries together referred to as “the Group” are involved in pharmacy business distributing medicines, medical supplies, cosmeceuticals, supplements, medical devices and other healthcare products as well as in business regarding invention business, developing, importing and distributing innovative healthcare products.

As at June 30, 2026 and December 31, 2025, the Group had 72 branches and 70 branches, respectively.

Details of the Group’s subsidiaries as at June 30, 2026 and December 31, 2025 were as follows:

No.	Name of the entity	Type of business	Country of incorporation	Group ownership interest (%)	
				As at June 30, 2026	As at December 31, 2025
Direct subsidiaries					
1	Icare Health Co., Ltd.	Distributing medicines, supplements, medical supplies, medical devices	Thailand	100	100
2	Healthiness Co., Ltd.	Importer and distributor of products including dietary supplements, medical devices, and healthcare related products	Thailand	100	100

The Company has extensive transactions and relationships with its related parties. Accordingly, the accompanying financial statements may not necessarily be indicative of the conditions that would have existed or the results of operations that would have occurred had the Company operated without such affiliations.

2. BASIS FOR PREPARATION AND PRESENTATION OF THE INTERIM CONSOLIDATED AND SEPARATE FINANCIAL STATEMENTS

- 2.1 These interim consolidated and separate financial statements are prepared in Thai Baht and in compliance with Thai Accounting Standard No. 34 “Interim Financial Reporting” and accounting practices generally accepted in Thailand. The Company presents the condensed notes to interim financial statements and the additional information is disclosed in accordance with the regulations of the Office of the Securities and Exchange Commission.
- 2.2 The English version of the consolidated and separate financial statements have been prepared from the Thai version of the consolidated and separate financial statements prepared by law. In the event of any conflict or different interpretation of the two different languages, the Thai version consolidated and separate financial statements in accordance with the Thai law is superseded.
- 2.3 The consolidated and separate statements of financial position as at December 31, 2025, presented herein for comparison, have been derived from the consolidated and separate financial statements of the Company for the year then ended which had been previously audited.
- 2.4 The unaudited results of operations presented in for the three-month and six-month periods ended June 30, 2026 is not necessarily an indication nor anticipation of the operating results for the full year.
- 2.5 Certain financial information which is normally included in the annual financial statements prepared in accordance with Thai Financial Reporting Standards (“TFRSs”), but which is not required for interim reporting purposes, has been omitted. Therefore, the interim consolidated and separate financial statements for the three-month and six-month periods ended June 30, 2026 should be read in conjunction with the audited consolidated and separate financial statements for the year ended December 31, 2025.
- 2.6 Material intercompany transactions between the Company and its subsidiaries have been eliminated from this interim consolidated financial statements.
- 2.7 Thai Financial Reporting Standards affecting the presentation and disclosure in the current period financial statements

During the period, the Group adopted the revised financial reporting standards issued by the Federation of Accounting Professions, which are effective for fiscal years beginning on or after January 1, 2026. These revisions were made to align the standards with the International Financial Reporting Standards and involve amendments to accounting requirements, as follows:

Thai Accounting Standard No. 21 “The Effects of Changes in Foreign Exchange Rates”, require entities to apply a consistent approach in assessing whether one currency is exchangeable into another currency, by specifying how to assess whether a currency is exchangeable and how to determine the exchange rate in circumstances in which exchangeability is lacking.

The adoption of these financial reporting standards does not have any significant impact on the Group's interim financial statements.

2.8 Thai Financial Reporting Standards announced in the Royal Gazette but not yet effective

The following TFRS Accounting Standards were announced in the Royal Gazette which will be effective for the financial statements for the period beginning on or after January 1, 2028, onwards.

Thai Financial Reporting Standard No. 18 “Presentation and Disclosures in Financial Statements”

Thai Financial Reporting Standard No. 18 (TFRS 18) replaces Thai Accounting Standard No. 1 (TAS 1), carrying forward many of the requirements in TAS 1 unchanged and complementing them with new requirements.

TFRS 18 introduces new requirements to:

- Present specified categories and defined subtotals in the statement of profit or loss
- Provide disclosures on management-defined performance measures (MPMs) in the notes to the financial statements
- Improve aggregation and disaggregation.

An entity is required to apply TFRS 18 for annual reporting periods beginning on or after January 1, 2028. Earlier application is permitted. An entity shall apply the transition requirements in TFRS 18, which require retrospective application in accordance with TAS 8 “Accounting Policies, Changes in Accounting Estimates and Errors”.

The Group's management anticipate that the application of TFRS 18 may have an impact on the Group's consolidated financial statements in future periods when it becomes effective.

3. MATERIAL ACCOUNTING POLICY INFORMATION

The interim financial statements have been prepared based on the basis, accounting policies and method of computation consistent with those used in the financial statements for the year ended December 31, 2025.

4. RELATED PARTY TRANSACTIONS

Related person or parties of the Company are defined as persons or entities that control the Company or are controlled by the Company, whether directly or indirectly or are under the same control as the Company including holding companies. In addition, related person or parties also include individuals owning, directly or indirectly, and interest in the voting shares of the Company, and have significant influence over the Company, key management personnel, directors or officers of the Company. This also applies to the close members of the family of such individuals and companies associated with these individuals.

In considering each possible related person or parties relationship, attention is directed to the substance of the relationship, not merely the legal form.

Transactions with related person or parties are conducted at market prices or, where no market price exists, at contractually agreed prices.

Relationships with related parties other than subsidiaries as at June 30, 2026 and December 31, 2025 were as follows:

	Name of entities	Type of business	Country of incorporation/ nationality	Nature of relationships
<u>Related companies</u>				
1	Siri Ravee Co., Ltd.	Building rental	Thailand	The same directors/directors are shareholders
2	Pakinpawat Co., Ltd.	Building rental	Thailand	Shareholder and director is a related person to key management
3	Pharmacy (Lopburi)	Distributing medicines, supplements, medical supplies, and medical devices	Thailand	A shareholder is a related person to the director
<u>Related person</u>				
1	Mrs. Mataya Bhandhukanonda		Thai	Director

Significant transactions with related parties for the three-month and six-month periods ended June 30, 2026 and 2025 were as follows:

	FOR THE THREE-MONTH PERIODS ENDED JUNE 30, CONSOLIDATED		SEPARATE	
	FINANCIAL STATEMENTS		FINANCIAL STATEMENTS	
	2026 Baht	2025 Baht	2026 Baht	2025 Baht
Subsidiaries				
Management income	-	-	14,720,995	15,260,792
Rental and service income	-	-	49,500	40,500
Interest income	-	-	10,192	9,644
Other related parties				
Sale of goods	13,676	9,028	-	-
Rental fee and service fee*	1,674,288	1,435,788	643,500	526,500
Utilities fee	294,310	284,011	98,413	84,907
Related person				
Rental fee and service fee*	380,625	380,625	-	-
Key management personnel				
Remuneration of key management personnel				
Short-term employee benefits	4,761,474	4,635,493	3,636,742	3,378,130
Post-employment benefits	130,521	151,029	121,793	144,454
Total	4,891,995	4,786,522	3,758,535	3,522,584

* Rental and service fee, included in the depreciation of the right-of-use assets in accordance with Thai Financial Reporting Standard No. 16 “Leases”.

	FOR THE SIX-MONTH PERIODS ENDED JUNE 30, CONSOLIDATED		SEPARATE	
	FINANCIAL STATEMENTS		FINANCIAL STATEMENTS	
	2026 Baht	2025 Baht	2026 Baht	2025 Baht
Subsidiaries				
Management income	-	-	31,042,472	31,338,718
Rental and service income	-	-	99,000	81,000
Interest income	-	-	10,192	41,288
Other related parties				
Sale of goods	17,758	23,705	-	-
Rental fee and service fee*	3,348,576	2,871,576	1,287,000	1,053,000
Utilities fee	545,496	531,010	179,133	156,909
Related person				
Rental fee and service fee*	761,250	761,250	-	-
Key management personnel				
Remuneration of key management personnel				
Short-term employee benefits	9,304,412	9,267,635	7,161,196	6,758,445
Post-employment benefits	261,041	302,059	243,585	288,908
Total	9,565,453	9,569,694	7,404,781	7,047,353

* Rental and service fee, included in the depreciation of the right-of-use assets in accordance with Thai Financial Reporting Standard No. 16 “Leases”.

The pricing policies are as follow;

Transaction	Pricing policy
Management income	Contract price
Rental and service income	Contract price
Interest income	Contract price
Sale of goods	Goods cost plus margin
Rental fee and service fee	Contract price
Utility fee	Contract price

Balances with related parties as at June 30, 2026 and December 31, 2025 were as follows:

	Notes	CONSOLIDATED FINANCIAL STATEMENTS		SEPARATE FINANCIAL STATEMENTS	
		As at June 30, 2026 Baht	As at December 31, 2025 Baht	As at June 30, 2026 Baht	As at December 31, 2025 Baht
Trade receivables					
Other related parties	7	-	1,520	-	-
Other receivables					
Subsidiaries	7	-	-	4,099,328	4,613,196
Accrued income					
Subsidiaries	7	-	-	57,446	-
Security deposits					
Other related parties	11	2,054,913	1,933,413	643,500	643,500
Other payables					
Subsidiaries		-	-	-	12,477
Other related parties		199,049	-	32,991	-
Total	12	<u>199,049</u>	<u>-</u>	<u>32,991</u>	<u>12,477</u>
Accrued expenses					
Other related parties	12	39,260	180,417	23,191	23,506

Significant agreements with related parties

Management service agreements

The Company entered into service agreements with 2 subsidiaries. The latter will provide office service and general management. The agreement duration is 1 year after the effective date and automatically extended after the expiration for 1 year, unless it is terminated by either party giving written notice of termination to the other party. In consideration for these services, the subsidiaries are committed to pay fee as specified in the agreements.

Rental and service agreement

The Company entered into a rental and service agreement with a subsidiary. The latter will provide office area and utilities service. The agreement duration is 3 years after the effective date as specified in the agreement. In case of renewal of the rental agreement, the lessee must inform through written notice to the counter party not less than 3 months before the end of the rental period. In consideration for these services, the subsidiary is committed to pay monthly fee as specified in the agreement.

Other commitments

	CONSOLIDATED FINANCIAL STATEMENTS		SEPARATE FINANCIAL STATEMENTS	
	As at June 30, 2026 Million Baht	As at December 31, 2025 Million Baht	As at June 30, 2026 Million Baht	As at December 31, 2025 Million Baht
Within one year	3.07	3.07	0.70	0.70
Over one year but within five years	3.84	5.38	0.88	1.23
Total	6.91	8.45	1.58	1.93

For the three-month periods ended June 30, 2026 and 2025, the Group recorded expenses according to the non-cancellable service agreements in the consolidated statements of comprehensive income of Baht 0.77 million and Baht 0.77 million, respectively. The Company recorded expenses according to the non-cancellable service agreements in the separate statements of comprehensive income of Baht 0.18 million and Baht 0.18 million, respectively.

For the six-month periods ended June 30, 2026 and 2025, the Group recorded expenses according to the non-cancellable service agreements in the consolidated statements of comprehensive income of Baht 1.54 million and Baht 1.54 million, respectively. The Company recorded expenses according to the non-cancellable service agreements in the separate statements of comprehensive income of Baht 0.35 million and Baht 0.35 million, respectively.

5. ADDITIONAL CASH FLOW INFORMATION

5.1 Non-cash transactions of plant and equipment for the six-month periods ended June 30, 2026 and 2025 were as follows:

	CONSOLIDATED FINANCIAL STATEMENTS		SEPARATE FINANCIAL STATEMENTS	
	2026 Baht	2025 Baht	2026 Baht	2025 Baht
Other payables for purchasing plant and equipment as at January 1,	1,628,404	1,573,250	85,653	-
<u>Add</u> Purchase of plant and equipment	11,782,059	20,150,122	342,198	214,993
<u>Less</u> Cash paid for purchase of plant and equipment	(12,280,765)	(20,140,358)	(400,183)	(214,993)
Other payables for purchasing plant and equipment as at June 30,	<u>1,129,698</u>	<u>1,583,014</u>	<u>27,668</u>	<u>-</u>

5.2 Reconciliation of liabilities arising from financing activities

Changes in the liabilities arising from financing activities, including both cash and non-cash changes classified as financing activities in the statements of cash flows, were as follows:

CONSOLIDATED FINANCIAL STATEMENTS					
As at June 30, 2026	Balance as at January 1, 2026 Baht	Financing cash flows Cash received Baht	Cash paid Baht	Non-cash changes Baht	Balance as at June 30, 2026 Baht
Lease liabilities	318,413,167	-	(30,314,258)	3,788,484	291,887,393
CONSOLIDATED FINANCIAL STATEMENTS					
As at June 30, 2025	Balance as at January 1, 2025 Baht	Financing cash flows Cash received Baht	Cash paid Baht	Non-cash changes Baht	Balance as at June 30, 2025 Baht
Lease liabilities	296,470,765	-	(25,646,521)	32,179,817	303,004,061
Accrued interest expense	-	-	(3,613)	3,613	-
SEPARATE FINANCIAL STATEMENTS					
As at June 30, 2026	Balance as at January 1, 2026 Baht	Financing cash flows Cash received Baht	Cash paid Baht	Non-cash changes Baht	Balance as at June 30, 2026 Baht
Lease liabilities	10,839,383	-	(1,080,000)	288,523	10,047,906
SEPARATE FINANCIAL STATEMENTS					
As at June 30, 2025	Balance as at January 1, 2025 Baht	Financing cash flows Cash received Baht	Cash paid Baht	Non-cash changes Baht	Balance as at June 30, 2025 Baht
Lease liabilities	9,758,554	-	(846,000)	211,260	9,123,814

6. CASH AND CASH EQUIVALENTS

Cash and cash equivalents as at June 30, 2026 and December 31, 2025 consisted of the following:

	CONSOLIDATED FINANCIAL STATEMENTS		SEPARATE FINANCIAL STATEMENTS	
	As at June 30, 2026 Baht	As at December 31, 2025 Baht	As at June 30, 2026 Baht	As at December 31, 2025 Baht
Cash on hand	3,494,455	4,548,442	-	-
Cheque on hand	-	1,070,435	-	-
Current accounts	975,593	2,954,495	49,279	131,636
Savings accounts	34,385,986	28,854,522	89,580	1,390,030
Total	38,856,034	37,427,894	138,859	1,521,666

7. TRADE AND OTHER CURRENT RECEIVABLES

Trade and other current receivables as at June 30, 2026 and December 31, 2025 consisted of the following:

	Note	CONSOLIDATED FINANCIAL STATEMENTS		SEPARATE FINANCIAL STATEMENTS	
		As at June 30, 2026 Baht	As at December 31, 2025 Baht	As at June 30, 2026 Baht	As at December 31, 2025 Baht
Trade receivables					
Related companies	4	-	1,520	-	-
Other companies		6,577,177	5,626,442	-	-
Total trade receivables		<u>6,577,177</u>	<u>5,627,962</u>	<u>-</u>	<u>-</u>
Other receivables					
Related companies	4	-	-	4,099,328	4,613,196
Other companies		15,829,541	19,225,560	378,633	744,727
<u>Less</u> Allowance for expected credit loss		<u>(48,794)</u>	<u>(106,251)</u>	<u>-</u>	<u>-</u>
Total other receivables		<u>15,780,747</u>	<u>19,119,309</u>	<u>4,477,961</u>	<u>5,357,923</u>
Value-added tax refundable			-		-
Prepaid expenses		5,526,021	3,348,850	272,347	150,386
Accrued interest income		319,858	676,400	320,186	676,400
Accrued income					
Related companies	4	-	-	57,446	-
Other companies		14,984,046	24,078,130	-	-
Advance payment for purchase inventory		<u>1,219,471</u>	<u>1,210,650</u>	<u>-</u>	<u>-</u>
Total		<u>44,407,320</u>	<u>54,061,301</u>	<u>5,127,940</u>	<u>6,184,709</u>

Aging analysis for trade receivables as at June 30, 2026 and December 31, 2025 consisted of the following:

	CONSOLIDATED FINANCIAL STATEMENTS		SEPARATE FINANCIAL STATEMENTS	
	As at June 30, 2026 Baht	As at December 31, 2025 Baht	As at June 30, 2026 Baht	As at December 31, 2025 Baht
Within credit terms	6,542,404	5,620,007	-	-
Overdue:				
Less than 3 months	<u>34,773</u>	<u>7,955</u>	<u>-</u>	<u>-</u>
	<u>6,577,177</u>	<u>5,627,962</u>	<u>-</u>	<u>-</u>
<u>Less</u> Allowance for expected credit loss	<u>-</u>	<u>-</u>	<u>-</u>	<u>-</u>
Total	<u>6,577,177</u>	<u>5,627,962</u>	<u>-</u>	<u>-</u>

The Group always measures the loss allowance for trade receivables at an amount equal to lifetime ECL. The expected credit losses on trade receivables are estimated using a provision matrix by reference to past default experience of the debtor and an analysis of the debtor's current financial position, adjusted for factors that are specific to the debtors.

8. INVENTORIES

Inventories as at June 30, 2026 and December 31, 2025 consisted of the following:

	CONSOLIDATED FINANCIAL STATEMENTS		SEPARATE FINANCIAL STATEMENTS	
	As at June 30, 2026 Baht	As at December 31, 2025 Baht	As at June 30, 2026 Baht	As at December 31, 2025 Baht
Professional healthcare	237,971,208	196,643,159	-	-
Personal healthcare	59,344,192	52,383,349	-	-
Medical equipment and home healthcare	43,986,097	38,634,140	-	-
Medical food	16,935,687	21,179,098	-	-
Consumables	1,098,528	648,202	-	-
	<u>359,335,712</u>	<u>309,487,948</u>	<u>-</u>	<u>-</u>
<u>Less</u> Allowance for diminution in value of inventories	(938,129)	(780,873)	-	-
Total	<u>358,397,583</u>	<u>308,707,075</u>	<u>-</u>	<u>-</u>

The amount of inventories recognized as expenses in the statements of comprehensive income for the three-month periods ended June 30, 2026 and 2025 included loss on diminution in value of inventories of Baht 0.03 million and Baht 0.07 million, respectively.

The amount of inventories recognized as expenses in the statements of comprehensive income for the six-month periods ended June 30, 2026 and 2025 included loss on diminution in value of inventories of Baht 0.16 million and Baht 0.12 million, respectively.

9. OTHER FINANCIAL ASSETS

Other financial assets as at June 30, 2026 and December 31, 2025, consisted of the following:

9.1 Other current financial assets

	CONSOLIDATED FINANCIAL STATEMENTS		SEPARATE FINANCIAL STATEMENTS	
	As at June 30, 2026 Baht	As at December 31, 2025 Baht	As at June 30, 2026 Baht	As at December 31, 2025 Baht
Financial assets mandatorily measured at FVTPL				
Unit trust	347,310,635	436,940,970	299,336,068	347,141,754
Total	<u>347,310,635</u>	<u>436,940,970</u>	<u>299,336,068</u>	<u>347,141,754</u>
Financial assets measured at amortized cost				
Bonds	25,022,780	75,083,845	25,022,780	75,083,845
<u>Less</u> Allowance for expected credit loss	(82,013)	(121,949)	(82,013)	(121,949)
Total	<u>24,940,767</u>	<u>74,961,896</u>	<u>24,940,767</u>	<u>74,961,896</u>
Total other current financial assets	<u>372,251,402</u>	<u>511,902,866</u>	<u>324,276,835</u>	<u>422,103,650</u>

9.2 Other non-current financial assets

	CONSOLIDATED FINANCIAL STATEMENTS		SEPARATE FINANCIAL STATEMENTS	
	As at June 30, 2026 Baht	As at December 31, 2025 Baht	As at June 30, 2026 Baht	As at December 31, 2025 Baht
Financial assets measured at amortized cost				
Bonds	7,409,239	7,393,045	7,409,239	7,393,045
Less Allowance for expected credit loss	(357,948)	(297,120)	(357,948)	(297,120)
Total	7,051,291	7,095,925	7,051,291	7,095,925
Total other non-current financial assets	7,051,291	7,095,925	7,051,291	7,095,925

The table below details the gross carrying amount and allowance for expected credit loss of financial assets measured at amortized cost by credit risk rating grades.

	CONSOLIDATED AND SEPARATE FINANCIAL STATEMENTS			
	As at June 30, 2026		As at December 31, 2025	
	Gross carrying amount Baht	Allowance for expected credit loss Baht	Gross carrying amount Baht	Allowance for expected credit loss Baht
Performing bonds	25,022,780	(82,013)	75,083,845	(121,949)
Underperforming bonds	7,409,239	(357,948)	7,393,045	(297,120)
Total	32,432,019	(439,961)	82,476,890	(419,069)

10. INVESTMENTS IN SUBSIDIARIES

Movements in investments in subsidiaries for the six-month periods ended June 30, were as follows:

	SEPARATE FINANCIAL STATEMENTS	
	2026 Baht	2025 Baht
Subsidiaries		
Balance as at January 1,	520,686,197	469,547,416
Share of profit of subsidiaries accounted for using the equity method	8,385,277	23,046,715
As at June 30,	529,071,474	492,594,131

Investments in subsidiaries as at June 30, 2026 and December 31, 2025 and dividend received for the three-month and six-month periods ended June 30, were as follows:

Company	SEPARATE FINANCIAL STATMENTS											
	Paid-up capital		Ownership interest		Cost method		Equity method		Dividend received			
	As at	As at	As at	As at	As at	As at	As at	As at	For the three-month	For the six-month		
	June 30,	December 31,	June 30,	December 31,	June 30,	December 31,	June 30,	December 31,	period ended June 30,	period ended June 30,		
	2026	2025	2026	2025	2026	2025	2026	2026	2026	2025	2026	2025
	Million	Million			Million	Million	Million	Million	Million	Million	Million	Million
	Baht	Baht	%	%	Baht	Baht	Baht	Baht	Baht	Baht	Baht	Baht
Icare Health Co., Ltd.	165	165	100	100	165	165	459	456	-	-	-	-
Healthiness Co., Ltd.	35	35	100	100	35	35	70	65	-	-	-	-
Total investments in subsidiaries					200	200	529	521	-	-	-	-

11. OTHER NON-CURRENT ASSETS

Other non-current assets as at June 30, 2026 and December 31, 2025 consisted of the following:

Note	CONSOLIDATED FINANCIAL STATEMENTS		SEPARATE FINANCIAL STATEMENTS	
	As at June 30, 2026 Baht	As at December 31, 2025 Baht	As at June 30, 2026 Baht	As at December 31, 2025 Baht
Security deposits				
Related companies	4	2,054,913	1,933,413	643,500
Other companies		31,824,237	83,000	99,800
Total		33,879,150	726,500	743,300

12. TRADE AND OTHER CURRENT PAYABLES

Trade and other current payables as at June 30, 2026 and December 31, 2025 were as follows:

Note	CONSOLIDATED FINANCIAL STATEMENTS		SEPARATE FINANCIAL STATEMENTS	
	As at June 30, 2026 Baht	As at December 31, 2025 Baht	As at June 30, 2026 Baht	As at December 31, 2025 Baht
Trade payables				
Other companies		169,637,754	-	-
Total trade payables		169,637,754	-	-
Other payables				
Related companies	4	199,049	32,991	12,477
Other companies		2,881,003	432,300	170,804
Total other payables		3,080,052	465,291	183,281
Treasury share payable		453,870	453,870	2,252,896
Advance received		1,410,129	-	-
Accrued expenses				
Related companies	4	39,260	23,191	23,506
Other companies		15,472,025	2,923,538	4,218,408
Revenue Department payable		1,577,733	412,439	427,796
Others		52,036	-	-
Total		191,722,859	4,278,329	7,105,887

13. LEGAL RESERVE

Section 116 of the Public Limited Companies Act B.E. 2535 requires that a company shall allocate not less than 5% of its annual net profit less the accumulated losses brought forward, if any, to a reserve account (“legal reserve”), until this account reaches an amount not less than 10% of the registered capital. The legal reserve is not available for dividend distribution.

As at June 30, 2026 and December 31, 2025, the Company’s legal reserve equaled to one-tenth of the registered share capital.

14. TREASURY SHARE

- 14.1 On May 14, 2025, the Board of Directors' Meeting No. 2/2025 passed a resolution for treasury stock program for financial management purpose in the amount not exceeding Baht 100 million. The number of ordinary shares to be repurchased is not exceeding 15,000,000 shares at a par value of Baht 0.50 per share or not exceeding 5.51 percent of total number of paid-up share capital of the Company of 272,000,000 shares. The Company repurchases its ordinary shares through the main board of the Stock Exchange of Thailand. The repurchase period is from May 19, 2025 to November 18, 2025. The Company completed the share repurchase project on November 18, 2025, the total outstanding treasury share of 8,550,000 shares in total amount of Baht 57.79 million which has been presented as deducted item under the shareholders' equity.
- 14.2 On December 8, 2025, the Board of Directors' Meeting No. 5/2025 passed a resolution for treasury stock program for financial management purpose in the amount not exceeding Baht 65 million. The number of ordinary shares to be repurchased is not exceeding 9,000,000 shares at a par value of Baht 0.50 per share or not exceeding 3.31 percent of total number of paid-up share capital of the Company of 272,000,000 shares. The Company repurchases its ordinary shares through the main board of the Stock Exchange of Thailand. The repurchase period is from December 12, 2025 to April 30, 2026. The Company completed the share repurchase project on April 30, 2026, the total outstanding treasury share of 8,900,000 shares in total amount of Baht 60.64 million which has been presented as deducted item under the shareholders' equity.
- 14.3 On May 8, 2026, the Board of Directors' Meeting No. 3/2026 passed a resolution for treasury stock program for financial management purpose in the amount not exceeding Baht 42 million. The number of ordinary shares to be repurchased is not exceeding 6,000,000 shares at a par value of Baht 0.50 per share or not exceeding 2.21 percent of total number of paid-up share capital of the Company of 272,000,000 shares. The Company repurchases its ordinary shares through the main board of the Stock Exchange of Thailand. The repurchase period is from May 15, 2026 to November 13, 2026.

As at June 30, 2026, the Company had repurchased its ordinary shares under such treasury stock program totaling 475,700 shares, total amount of Baht 2.78 million which has been presented as deducted item under the shareholders' equity.

According to letter No. Gor Lor Tor. Chor Sor. (Vor) 2/2548 of the Office of the Securities and Exchange Commission, dated February 14, 2005, concerning the acquisition of treasury shares, a public limited company may purchase back treasury shares in an amount not exceeding the amount of its retained earnings and is to appropriate an equal amount of retained earnings to a reserve for treasury shares, which must be maintained until the Company either sells the treasury shares or reduces its paid-up share capital by an amount equal to the value of the treasury shares which it could not sell. As at March 31, 2026, the Company appropriated the full required amount of retained earnings to the treasury share reserve.

15. BASIC EARNINGS PER SHARE

The calculations of earnings per share for the three-month and six-month periods ended June 30, 2026 and 2025 were based on the profit for the periods attributable to ordinary shareholders of the Company and the number of weighted ordinary shares outstanding held by shareholders as follows:

	FOR THE THREE-MONTH PERIODS ENDED JUNE 30, CONSOLIDATED FINANCIAL STATEMENTS		SEPARATE FINANCIAL STATEMENTS	
	2026	2025	2026	2025
Basic earnings per share				
Profit attributable to owners of the Company (Baht)	311,470	16,804,016	311,470	16,804,016
Weighted-average number of ordinary shares (Share)	254,800,354	270,697,895	254,800,354	270,697,895
Basic earnings per share (Baht)	0.001	0.06	0.001	0.06

	FOR THE SIX-MONTH PERIODS ENDED JUNE 30, CONSOLIDATED FINANCIAL STATEMENTS		SEPARATE FINANCIAL STATEMENTS	
	2026	2025	2026	2025
Basic earnings per share				
Profit attributable to owners of the Company (Baht)	18,852,933	37,262,886	18,852,933	37,262,886
Weighted-average number of ordinary shares (Share)	256,963,179	271,345,350	256,963,179	271,345,350
Basic earnings per share (Baht)	0.07	0.14	0.07	0.14

16. SEGMENT INFORMATION

The Group presented the financial information segment in respect of the Group under management approach. Operating segment is based on the Group's management, the management structure and internal reporting.

Business segments

The Group operates in a single line of business which is the pharmacy business by distributing medicines, medical supplies, cosmeceuticals, supplements, medical devices and other healthcare products including inventing, developing, importing and distributing innovative health products. All of them are classified as health products for external use and dietary supplements. Therefore, the management considers that the Group has only one business segment.

Geographical segments

The Group operates in a single geographic area in Thailand. Therefore, the management considers that the Group has only one geographical segment.

Information about transactions with major customers

For the three-month and six-month periods ended June 30, 2026 and 2025, the Group had no revenues from sales with a single external customer contributed 10% or more to the Group's total revenue.

17. COMMITMENTS AND CONTINGENT LIABILITIES

17.1 Capital commitments

As at June 30, 2026 and December 31, 2025, the Group had capital commitments in respect of building improvement approximately Baht 0.70 million and Baht 0.49 million, respectively.

17.2 Non-cancellable service agreements

The Group had future minimum lease payments required under non-cancellable service agreements as follows:

	CONSOLIDATED FINANCIAL STATEMENTS		SEPARATE FINANCIAL STATEMENTS	
	As at June 30, 2026 Million Baht	As at December 31, 2025 Million Baht	As at June 30, 2026 Million Baht	As at December 31, 2025 Million Baht
Within one year	34.19	32.65	-	-
Over one year to five years	27.29	24.08	-	-
Total	61.48	56.73	-	-

For the three-month periods ended June 30, 2026 and 2025, the Group recorded expenses according to the non-cancellable service agreements in the consolidated statements of comprehensive income of Baht 10.40 million and Baht 9.75 million, respectively.

For the six-month periods ended June 30, 2026 and 2025, the Group recorded expenses according to the non-cancellable service agreements in the consolidated statements of comprehensive income of Baht 20.31 million and Baht 19.66 million, respectively.

18. FAIR VALUE MEASUREMENTS

18.1 Financial instruments measured at fair value

Certain financial assets of the Group and the Company are measured at fair value at the end of reporting period. The following table gives information about how the fair values of these financial assets are determined.

Financial assets	CONSOLIDATED FINANCIAL STATEMENTS		Fair value hierarchy	Valuation techniques and key inputs in fair value measurements
	Fair value As at June 30, 2026 Baht	Fair value As at December 31, 2025 Baht		
Other current financial assets				
Financial assets mandatorily measured at FVTPL				
Unit trust	347,310,635	436,940,970	2	Net asset value of unit trust at the last working day of the reporting period

Financial assets	SEPARATE FINANCIAL STATEMENTS			
	Fair value		Fair value hierarchy	Valuation techniques and key inputs in fair value measurements
	As at	As at		
	June 30, 2026 Baht	December 31, 2025 Baht		
Other current financial assets				
Financial assets mandatorily measured at FVTPL				
Unit trust	299,336,068	347,141,754	2	Net asset value of unit trust at the last working day of the reporting period

18.2 Financial instruments not measured at fair value

As at June 30, 2026 and December 31, 2025, fair value of cash and cash equivalents, trade and other current receivables, and trade and other current payables are considered to approximate their respective carrying value in the consolidated and separate statements of financial position since the fair value are predominantly subject to market interest rate and mature in the short-term.

The transactions disclosed in the following tables, are considered that the carrying amounts recognized in the consolidated and separate statements of financial position are different from their fair values as follows:

Financial assets	CONSOLIDATED AND SEPARATE FINANCIAL STATEMENTS				
	As at June 30, 2026		As at December 31, 2025		Fair value hierarchy
	Carrying amount	Fair value	Carrying amount	Fair value	
Other current financial assets					
Financial assets measured at amortized cost					
Bonds	24,940,767	25,142,477	74,961,896	75,445,329	2
Other non-current financial assets					
Financial assets measured at amortized cost					
Bonds	7,051,291	7,044,628	7,095,925	7,044,628	2

For bonds, their fair values are determined based on the prices approached by the Thai Bond Market Association.

19. DIVIDEND PAID

On April 24, 2026, the Annual General Meeting of the Company passed a resolution to distribute an annual dividend for the year 2025 at Baht 0.22 per share, totaling Baht 56,648,130. The dividend was paid on May 15, 2026.

On April 25, 2025, the Annual General Meeting of the Company passed a resolution to distribute an annual dividend for the year 2024 at Baht 0.17 per share, totaling Baht 46,240,000. The dividend was paid on May 15, 2025.

20. APPROVAL OF THE FINANCIAL STATEMENTS

The financial statements were authorized for issuance by the Board of Directors of the Company on August 13, 2026.